Hematologic Malignancies Practice Test

Supportive care and medications are highly relevant in the management of myelodysplastic syndromes (MDS). This condition is characterized by ineffective hematopoiesis, leading to various degrees of cytopenia. Supportive measures primarily aim to alleviate symptoms and improve the quality of life for patients.

One of the main supportive interventions involves blood product transfusions, which are used to address anemia and thrombocytopenia. Additionally, medications such as erythropoiesis-stimulating agents may be employed to enhance red blood cell production. Patients may also benefit from the use of growth factors and iron chelation therapy to manage transfusion-related iron overload.

Other supportive care aspects include infection prophylaxis and management, as patients with MDS are at an elevated risk for infections due to neutropenia. Counseling and education on the disease process, along with palliative care options, form an essential part of the overall treatment strategy to ensure the best possible outcomes for these patients.

The other options imply more aggressive treatment approaches that may not be suitable for all patients with MDS, who often are elderly or have comorbidities that make intensive treatments like chemotherapy and bone marrow transplantation less feasible. Radiotherapy and surgery are not typical treatment modalities for MDS,